Biogen Reports Q2 2025 Earnings with Revenue Growth and EPS Increase
Biogen (BIIB) reported Q2 2025 earnings with revenue of $2.8 billion, a 7% increase, driven by launch products and the U.S. MS business. Non-GAAP diluted EPS was $5.25, up 4%, with a $0.26 IPR&D expense impact. The company also highlighted strong performance from several products, including LEQEMBI and ZURZUVAE.
Tickers: $BIIB
Topics: Biogen Earnings Report Launch Products LEQEMBI MS Business Revenue Growth SPINRAZA